Navigation Links
ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins
Date:4/4/2013

t could also have implications for the late-stage oral HIF-PH inhibitors in development, for example Akebia Therapeutics' AKB-6548 or FibroGen's/Astellas's FG-4592/ASP1517."

The BioTrends' TreatmentTrends: Nephrology (US) Q4 2012 report, found that over 20 percent of nephrologists expect to use AKB-6548 and FG-4592/ASP1517 products after ESA failures, respectively. Late stage oral HIF-PH inhibitors manufacturers must be considering when and how these agents will be used, especially when physicians are waiting longer to initiate ESAs.ChartTrends®: Renal Anemia in CKD-ND 2012 (U.S.) is a syndicated report series, in which 226 U.S. nephrologists provide patient chart data on 1,130 CKD-ND patients in the U.S. to uncover the actual management related to renal anemia. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with kidney disease. The Q1 2013 wave published in March 2013 and the Q2 2013 wave will publish in June with survey comments due April 10, 2013.

About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharma
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
2. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
3. Medifast, Inc. Announces Favorable Resolution of Securities Class Action Lawsuit
4. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
5. Class III Obese Patients Experience Adverse Events More Frequently Than the General Adverse Event Patient Population
6. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
9. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
10. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
11. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 ... antivirals has amplified with rising incidence rates and ... absence of a preventative vaccine. Change is underway ... and interferon regimens towards highly effective, easily-tolerated, interferon-free ... http://photos.prnewswire.com/prnh/20140728/130662 Gilead,s mega blockbuster ...
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
... ZURICH , July 19, 2010 Today, Novo Nordisk ... designed to investigate the effects of modern insulins in,the management of type 2 diabetes.[1] ... Spanning 28 countries across ... largest observational study,in insulin therapy. , , ...
... July 16 Human erythropoietin (EPO) is a ... and spinal cord injury, and Parkinson,s disease. However, EPO drug ... cross the blood-brain barrier (BBB). In acute stroke or brain ... the insult when neuroprotection is still possible. Therefore, large molecule ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:7/29/2014)... rates rise in association with extremely hot weather. The ... 2003, for example, resulted in about 22,000 extra deaths. ... at the Institute of Epidemiology II at the Helmholtz ... the number of deaths caused by cardiovascular disease in ... temperatures in the study. , "Our findings confirm the ...
(Date:7/29/2014)... handle stressful situations better than others, and it,s ... show differences in how they respond. , Researchers ... brains of genetically identical mice that predicts how ... , The findings, published July 29 in ... prevent potential consequences of chronic stress -- such ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Foot Levelers ... lecturer at the Florida Chiropractic Association (FCA) National Convention ... Effects on the Kinetic Chain Changes on Thursday, August ... talk is focusing on the positive impact functional foot ... such as low back pain, plantar fasciitis, and hammertoes. ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... of Oaks Development,Group announced today the company closed on ... 3603 Paesanos Parkway in north central,San Antonio. The ... 1604 and,Northwest Military Highway, will feature the company,s unique ... tenants, equity,investors and the developer. , ...
... and John Centrello decided to bank their baby,s cord blood with M.A.Z.E. ... hoping never to use it, but wanted to have it just in ... ... While pregnant, Danielle and John Centrello decided to bank their baby,s ...
... December 8, 2008Medical specialists at the nation,s largest professional ... have about data presented by the FDA in support ... and the potential effect of the federal agency,s analyses ... are to be conducted in the future. , It ...
... Unilens Vision Inc.,(OTC Bulletin Board: UVICF; TSX Venture ... specialty contact lenses,today announced the acquisition of the ... Inc. located in Michigan. , ... agreement, Unilens acquired certain assets of Aero,Contact Lens, ...
... chronic hepatitis C and advanced liver disease with long-term ... and liver inflammation, but the treatment did not slow ... study finds. , These findings come from the clinical ... and are reported in the Dec. 4 issue of ...
... Cancer Report Released by IARC; U.S. Groups List Six Critical Steps ... , ATLANTA, Dec. 9 Despite ... men and women in the United States continue to decline, cancer ... the year 2010, and low- and middle-income countries will feel the ...
Cached Medicine News:Health News:Oaks Development Group Closes on Third San Antonio Project 2Health News:Oaks Development Group Closes on Third San Antonio Project 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 2Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 4Health News:Unilens Vision Acquires Aero Contact Lens, Inc. 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 3Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 2Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 3Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 4Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 5Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 6
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: